权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an

肿瘤中大分子和病毒载体的转运：细胞毒性和病毒载体的影响

基本信息

批准号：
8458984
负责人：
YVES BOUCHER
金额：
$ 26.2万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-07-01 至 2014-10-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8458984
关键词：
Affect Antibodies Apoptosis Blocking Antibodies Blood Blood Vessels Caliber Cells Clinical Cyclophosphamide Cytoskeleton Cytotoxic agent Endothelial Cells Endothelium Extravasation Fatty acid glycerol esters Frozen Sections Funding Half-Life Health Herpesvirus 1 Hour Human Mammary Carcinoma Immunodeficient Mouse Implant Injection of therapeutic agent Integrins Laser Scanning Microscopy Lung Malignant Epithelial Cell Mammary Neoplasms Mammary gland Measures Movement Mus Neoplasm Metastasis Neoplasms in Vascular Tissue Oncolytic Oncolytic viruses Penetration Perfusion Primary Neoplasm Schedule Simplexvirus Structure Testing Time Treatment Efficacy Treatment Protocols Vascular remodeling Viral Viral Vector Virion Virus base cancer cell cell killing clinical efficacy cytotoxic density docetaxel improved in vivo interstitial intravenous injection intravital microscopy multi-photon neoplastic cell particle prevent success translational study tumor tumor growth

项目摘要

DESCRIPTION (provided by applicant): Oncolytic virotherapy is a promising approach because the efficient transduction and cancer cell-specific viral replication can boost therapeutic efficacy. However, the large size of oncolytic viruses hinders their transvascular and interstitial movement, thus significantly limiting their delivery to cancer cells and anti- tumor efficacy. Our findings from the current funding period showed that cancer cell apoptosis produced void spaces and channel-like structures, which enhanced the initial delivery, viral spread and therapeutic efficacy of oncolytic herpes-simplex-virus (HSV) after intratumor injection. But in order to improve the systemic efficacy of oncolytic virotherapy targeted both at primary and metastatic tumors, it is essential to identify agents (e.g., cytotoxic agents) or strategies that will improve the vascular extravasation and intratumoral distribution of viral particles injected intravenously. In the proposed studies we will test the hypothesis that targeting tumor blood vessels will improve the delivery of viral vectors and the anti-tumor efficacy of oncolytic HSV. The tumor vasculature will be targeted with endothelial cell targeting agents (anti-integrin 14 or 15 blocking antibodies) or cytotoxics (cyclophosphamide, docetaxel) that target both endothelial and cancer cells. The agents selected are known to induce endothelial cell apoptosis and remodel the tumor vasculature. We will use multiphoton laser scanning microscopy to measure the vascular pore cutoff size of large particles, vascular remodeling (e.g. vessel density, diameter, perfusion), and virus extravasation and spread in human mammary carcinoma cells implanted in mammary fat pad windows in immunodeficient mice. Because of the short-half life of virus in blood (HSV ~ 3 hours), we will determine for each agent the peak-time of large particle extravasation. Based on the peak-time of particle extravasation, oncolytic HSV will be injected systemically and the fraction of vessels associated with infected cells will be determined. The correlation between endothelial apoptosis and particle extravasation will be assessed in tumor sections. We will test if the administration of endothelial targeting agents or cytotoxics before the intravenous injection of oncolytic virus will produce a longer tumor growth delay in mammary fat pad tumors and reduce spontaneous metastasis formation in the lung. We will also determine if the repeated administration (cycling) of cytotoxics or endothelial targeting agents with oncolytic HSV will improve the intratumoral distribution of large particles and the spread and therapeutic efficacy of oncolytic HSV. We expect that the results of these translational studies will identify single agents and / or approaches that will enhance the vascular extravasation and intratumoral spread of virus, and the efficacy of oncolytic virotherapy targeted at tumors.

描述（申请人提供）：溶瘤病毒治疗是一种很有前途的方法，因为有效的转导和癌细胞特异性的病毒复制可以提高治疗效果。然而，溶瘤病毒的大体积阻碍了它们的跨血管和间质运动，从而极大地限制了它们向癌细胞的传递和抗肿瘤效果。本研究发现，肿瘤细胞凋亡产生空腔和通道样结构，从而增强肿瘤内注射溶瘤性单纯疱疹病毒（HSV）的初始递送、病毒传播和治疗效果。但是，为了提高针对原发性和转移性肿瘤的溶瘤病毒治疗的全身疗效，有必要确定药物（如细胞毒性药物）或策略，以改善静脉注射病毒颗粒的血管外渗和肿瘤内分布。在拟议的研究中，我们将验证靶向肿瘤血管将改善病毒载体的传递和溶瘤性HSV的抗肿瘤功效的假设。肿瘤血管将被内皮细胞靶向药物（抗整合素14或15阻断抗体）或细胞毒素（环磷酰胺，多西紫杉醇）靶向内皮细胞和癌细胞。所选择的药物已知可诱导内皮细胞凋亡和重塑肿瘤血管系统。我们将使用多光子激光扫描显微镜测量大颗粒血管孔切断大小、血管重塑（如血管密度、直径、灌注）以及病毒在免疫缺陷小鼠乳腺脂肪垫窗口植入的人乳腺癌细胞中的外渗和扩散。由于病毒在血液中的半衰期短（HSV ~ 3小时），我们将确定每种病原体的大颗粒外渗高峰时间。根据颗粒外渗的高峰时间，将全身注射溶瘤性HSV，并确定与感染细胞相关的血管比例。内皮细胞凋亡与颗粒外渗的相关性将在肿瘤切片中进行评估。我们将测试在静脉注射溶瘤病毒之前给予内皮靶向药物或细胞毒素是否会使乳腺脂肪垫肿瘤的生长延迟更长时间，并减少肺部的自发转移形成。我们还将确定细胞毒素或内皮靶向药物与溶瘤性HSV的重复给药（循环）是否会改善肿瘤内大颗粒的分布以及溶瘤性HSV的扩散和治疗效果。我们期望这些转化性研究的结果将确定单一药物和/或方法，以增强病毒的血管外渗和肿瘤内扩散，以及针对肿瘤的溶瘤病毒治疗的疗效。